A recent Bayesian network meta-analysis [17] of RA patients whose first line anti-TNF failed found that patients receiving bDMARDs with other MOA did better than patients receiving a second anti-TNF agent, as measured by American College of Rheumatology 20 (ACR20) response criteria. This evidence concerns the gene TNF and rheumatoid arthritis.